Whole-body positron emission tomography using 18F-fluorodeoxyglucose compared to standard procedures for staging patients with Hodgkin's disease.
暂无分享,去创建一个
G. Jerusalem | P. Rigo | G. Fillet | P. Paulus | Y Beguin | P Rigo | Y. Beguin | G Jerusalem | M F Fassotte | F Najjar | P Paulus | G Fillet | M. Fassotte | F. Najjar
[1] S. Reske,et al. 18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] A. Wolf,et al. Metabolic trapping as a principle of oradiopharmaceutical design: some factors resposible for the biodistribution of [18F] 2-deoxy-2-fluoro-D-glucose. , 1978, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[3] S. Reske,et al. Role of attenuation correction for fluorine-18 fluorodeoxyglucose positron emission tomography in the primary staging of malignant lymphoma , 1999, European Journal of Nuclear Medicine.
[4] M Tubiana,et al. Report of the Committee on Hodgkin's Disease Staging Classification. , 1971, Cancer research.
[5] O. Warburg. [Origin of cancer cells]. , 1956, Oncologia.
[6] G. Jerusalem,et al. Persistent tumor 18F-FDG uptake after a few cycles of polychemotherapy is predictive of treatment failure in non-Hodgkin's lymphoma. , 2000, Haematologica.
[7] G Muehllehner,et al. Singles transmission in volume-imaging PET with a 137Cs source. , 1995, Physics in medicine and biology.
[8] G. Jerusalem,et al. Whole-body positron emission tomography using 18F-fluorodeoxyglucose for posttreatment evaluation in Hodgkin's disease and non-Hodgkin's lymphoma has higher diagnostic and prognostic value than classical computed tomography scan imaging. , 1999, Blood.
[9] A. Buck,et al. Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998, European Journal of Nuclear Medicine.
[10] E. Merkle,et al. Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.
[11] J Kotzerke,et al. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.
[12] M E Phelps,et al. Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[13] M Schwaiger,et al. Positron emission tomography in non-Hodgkin's lymphoma: assessment of chemotherapy with fluorodeoxyglucose. , 1998, Blood.
[14] R. Castellino,et al. Computed tomography, lymphography, and staging laparotomy: correlations in initial staging of Hodgkin disease. , 1984, AJR. American journal of roentgenology.
[15] G Hör,et al. Positron emission tomography (PET) for staging and evaluation of response to treatment in patients with Hodgkin's disease. , 1999, Leukemia & lymphoma.
[16] A. Aisenberg. Problems in Hodgkin's disease management. , 1999, Blood.
[17] A. Hagenbeek,et al. Clinical staging versus laparotomy and combined modality with MOPP versus ABVD in early-stage Hodgkin's disease: the H6 twin randomized trials from the European Organization for Research and Treatment of Cancer Lymphoma Cooperative Group. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[18] G. Jerusalem,et al. Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.
[19] J M Hoffman,et al. Semiquantitative and visual analysis of FDG-PET images in pulmonary abnormalities. , 1994, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.
[20] J. D. van der Walt,et al. Detection of lymphoma in bone marrow by whole-body positron emission tomography. , 1998, Blood.
[21] R. Castellino,et al. Hodgkin disease: contributions of chest CT in the initial staging evaluation. , 1986, Radiology.
[22] M Tubiana,et al. Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[23] D. Bumann,et al. Whole-body positron emission tomography (PET) for diagnosis of residual mass in patients with lymphoma. , 1997, Annals of oncology : official journal of the European Society for Medical Oncology.